Send us Feedback

Vical (VICL)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

VICL » Topics » EQUITY COMPENSATION PLAN INFORMATION

This excerpt taken from the VICL DEF 14A filed Apr 3, 2009.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information as of December 31, 2008, with respect to our equity compensation plan in effect on that date.

 

     Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights (a)		    Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights (b)		    Number of Securities
Remaining Available for
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected
in Column (a)) (c)

Equity compensation plans approved by stockholders

    3,993,750    $ 7.40    2,454,489

 

27

This excerpt taken from the VICL DEF 14A filed Apr 7, 2008.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information as of December 31, 2007, with respect to both of our equity compensation plans in effect on that date.

 

     Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights (a)		    Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights (b)		    Number of Securities
Remaining Available for
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected
in Column (a)) (c)

Equity compensation plans approved by stockholders

    3,804,480    $ 8.06    2,695,998

 

22

This excerpt taken from the VICL DEF 14A filed Apr 20, 2007.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information as of December 31, 2006, with respect to both of our equity compensation plans in effect on that date.

 

     Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights (a)		    Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights (b)		    Number of Securities
Remaining Available for
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected
in Column (a)) (c)

Equity compensation plans approved by stockholders (1)

    3,427,288    $ 8.64    2,106,379
(1) Includes the Stock Incentive Plan and the Directors’ Stock Plan. As of December 31, 2006, we did not have any equity compensation plans that were not approved by our stockholders.

 

22

This excerpt taken from the VICL DEF 14A filed Apr 17, 2006.

EQUITY COMPENSATION PLAN INFORMATION

 

The following table provides certain information as of December 31, 2005, with respect to both of our equity compensation plans in effect on that date.

 

     Number of Securities to be
Issued Upon Exercise of
Outstanding Options,
Warrants and Rights
(a)
    Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
   

Number of Securities
Remaining Available for
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected in Column (a))

(c)

Equity compensation plans approved by stockholders (1)

    3,790,474    $ 9.09    864,747
(1) Includes the Stock Incentive Plan and the Directors’ Stock Plan. As of December 31, 2005, we did not have any equity compensation plans that were not approved by our stockholders.

 

26

This excerpt taken from the VICL DEF 14A filed Apr 8, 2005.

EQUITY COMPENSATION PLAN INFORMATION

 

The following table provides certain information as of December 31, 2004, with respect to both of our equity compensation plans in effect on that date.

 

     Number of Securities to be
Issued Upon Exercise of
Outstanding Options,
Warrants and Rights
(a)
    Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)
   

Number of Securities
Remaining Available for
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected in Column (a))

(c)

Equity compensation plans approved by stockholders (1)

    3,850,736    $ 9.82    1,026,754
(1) Includes the Stock Incentive Plan and the Directors’ Stock Plan. As of December 31, 2004, we did not have any equity compensation plans that were not approved by our stockholders.

 

20

EXCERPTS ON THIS PAGE:

DEF 14A
Apr 3, 2009
DEF 14A
Apr 7, 2008
DEF 14A
Apr 20, 2007
DEF 14A
Apr 17, 2006
DEF 14A
Apr 8, 2005

RELATED TOPICS for VICL:

"EQUITY COMPENSATION PLAN INFORMATION" elsewhere:

ACADIA Pharmaceuticals (ACAD)
Affymax (AFFY)
ARIAD Pharmaceuticals (ARIA)
BioCryst Pharmaceuticals (BCRX)
Biopure (BPUR)
Clinical Data (CLDA)
Corcept Therapeutics (CORT)
Curis (CRIS)
EPIX Pharmaceuticals (EPIX)
EXACT Sciences (EXAS)
GenVec (GNVC)
GTC Biotherapeutics (GTCB)
Idenix Pharmaceuticals (IDIX)
IGI (IG)
ImmunoGen (IMGN)
Inhibitex (INHX)
InterMune (ITMN)
Metabasis Therapeutics (MBRX)
Memory Pharmaceuticals (MEMY)
Micromet (MITI)
Matritech (MZT)
Biota Pharmaceuticals, Inc. (NABI)
Neose Technologies (NTEC)
Neurobiological Technologies (NTII)
Osiris Therapeutics (OSIR)
Progenics Pharmaceuticals (PGNX)
Sangamo BioSciences (SGMO)
Sunesis Pharmaceuticals (SNSS)
Savient Pharmaceuticals (SVNT)
AmpliPhi Biosciences Corp (TGEN)
Theravance (THRX)
Trubion Pharmaceuticals (TRBN)
SYNAGEVA BIOPHARMA CORP (TRMS)
XOMA (XOMA)
CORD BLOOD AMERICA (CBAI)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki